Top News and Expert Insights for World Sickle Cell Day 2025

The landscape of care for sickle cell disease (SCD) is rapidly changing. On a single day in 2023—December 8—the field of hematology was shaken by the FDA’s simultaneous approval of 2 gene therapy products for the treatment of SCD: Vertex Pharmaceuticals' and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel; marketed as Casgevy) and bluebird bio’s lovotibeglogene autotemcel (lovo-cel; marketed as Lyfgenia). While these products continue to be rolled out to patient populations, a number of other advanced therapeutics are in clinical-stage development for SCD.